Active Clinical Trials and Research Studies
Research Studies Need Participants
When we look back at the advances that have been made over the last 20 years in Alzheimer’s research and review recent research advances, we feel very hopeful that 20 years from now we will be able to prevent the current devastating effects of the disease. Each step forward requires people willing to participate in research.
| Research Study | Eligibility Criteria | Study Description |
|---|---|---|
| Emory Alzheimer's Disease Research Center Honor Research Registry Longitudinal study of changes in memory and other cognitive skills |
| |
| Brain Donation Program |
| The purpose of this research study is to follow individuals who have participated in ACTC and/or ATRI research studies, over the phone every 6 months, until the time of death. All participants who join this study are registered members of the ACTC Brain Donation Program. |
| ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) |
| The ALLFTD study looks at people with a brain disease called frontotemporal dementia (FTD), including those who have it and family members who might get it. The goal is to learn how the disease changes over time and help with future treatments. The study has two parts: one does a full check-up every year, and the other collects only basic health info and body samples like blood or saliva. |
| Charlie and Harriet Shaffer Cognitive Empowerment Program (CEP) |
| The Charlie and Harriet Shaffer Cognitive Empowerment Program aims to provide people with Mild Cognitive Impairment (MCI) and their Care Partners and families with an opportunity to participate in comprehensive lifestyle programs that promote joy, purpose, health, and wellness. Members of the program will receive personalized assessments designed to empower them as they seek to implement healthy brain interventions. |
| DIAN-TU-002 |
| The purpose of this research study is to test the study drug, referred to as remternetug, to determine its effectiveness for the study treatment of asymptomatic (at risk) Alzheimer's disease in individuals with AD-causing mutations. This study will also investigate the effects of remternetug on biomarkers (measures of the disease, including brain scans, blood, and spinal fluid tests), examine safety data to identify any potential benefits or risks, and examine how well participants can tolerate remternetug. Stage 1 will determine if treatment with the study drug prevents or reverses amyloid beta (Aβ) accumulation compared with placebo in participants with dominantly inherited Alzheimer's disease (DIAD). Stage 2 will evaluate the effect of early anti-amyloid treatment on downstream biomarkers of AD in treated participants compared to external control groups. |
| Emory Healthy Aging Study (EHAS) |
| The Emory Healthy Aging Study is a longitudinal study focused on helping us better understand how we age and age-related disease through the creation of a large database of health history information provided by participants. |
| Emory Healthy Brain Study (EHBS) |
| The Emory Healthy Brain Study is a longitudinal sub-study of the Emory Healthy Aging Study focused on identifying the biomarkers of Alzheimer’s disease and other forms of dementia. |
| Goizueta Institute Biorepository Cognitive |
| |
| Longitudinal Early-Onset Alzheimer's Disease Study (LEADS) |
| This study looks at the differences between people who get Alzheimer’s disease early (before age 65), those who get it later, and older adults without memory problems. The goal is to better understand what causes Alzheimer’s and how it affects the brain. |
| HONOR/ Memory/ UDS |
| Memory at Emory is a longitudinal study designed to learn more about neurologic disorders. Criteria for participation includes individuals 70 years of age or older. |
| Precision Aging Network (PAN) | The Precision Aging Network seeks help to answer critical questions: What impacts healthy brain function as we age? How can optimal brain function be maintained across our entire lives? For you as an individual, how can we predict, prevent, or slow unwanted changes in cognition? | |
| SuperAger |
| |
| Synaptic Therapy Alzheimer’s Research Trial (START) | The START study tests an investigational treatment to see if it can safely slow memory loss from Alzheimer’s disease (AD). The study lasts about two years, and you will be asked to make about 24 visits to the study site to see doctors who will closely monitor your health. By participating, you or your loved one could be an important part of finding new treatments for people with AD. |
Different Types of Research Studies
Research on Alzheimer’s is rapidly advancing on several fronts.
Researchers are:
- Testing potential new medications they hope will be even more effective than currently available treatments
- Using medications approved for other uses (for example, cholesterol lowering medications) as potential treatments for Alzheimer’s
- Looking for ways to identify mild cognitive impairment and Alzheimer’s disease early as well as monitor the progress of the disease
- Learning more about the transition from aging without memory problems to mild cognitive impairment and Alzheimer’s
- Studying how to help individuals and families cope with the disease
Contact Us
Crystal Davis
Please contact our Senior Project Support Specialist for more information.
Phone:
Email: